Media coverage about Applied Genetic Technologies (NASDAQ:AGTC) has been trending somewhat positive on Tuesday, Accern Sentiment Analysis reports. Accern identifies negative and positive press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Applied Genetic Technologies earned a news impact score of 0.15 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 47.4601163108938 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Several equities research analysts have issued reports on AGTC shares. Cantor Fitzgerald set a $9.00 target price on Applied Genetic Technologies and gave the stock a “hold” rating in a research note on Friday, October 6th. Zacks Investment Research cut Applied Genetic Technologies from a “hold” rating to a “strong sell” rating in a research note on Tuesday, October 31st. Wedbush reissued an “outperform” rating and set a $9.00 target price on shares of Applied Genetic Technologies in a research note on Wednesday, November 8th. HC Wainwright reissued a “buy” rating and set a $8.00 target price on shares of Applied Genetic Technologies in a research note on Wednesday, November 8th. Finally, BMO Capital Markets restated an “outperform” rating and set a $7.00 price target (down from $14.00) on shares of Applied Genetic Technologies in a research report on Thursday, September 14th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $10.17.
Applied Genetic Technologies (AGTC) traded down $0.05 on Tuesday, hitting $3.75. The stock had a trading volume of 48,700 shares, compared to its average volume of 165,381. Applied Genetic Technologies has a 1-year low of $3.25 and a 1-year high of $10.15.
Applied Genetic Technologies (NASDAQ:AGTC) last released its quarterly earnings results on Wednesday, September 13th. The biotechnology company reported ($0.18) EPS for the quarter, missing the consensus estimate of $0.22 by ($0.40). Applied Genetic Technologies had a negative return on equity of 2.86% and a negative net margin of 8.78%. The firm had revenue of $8.30 million for the quarter, compared to analysts’ expectations of $12.39 million. During the same quarter in the prior year, the business earned $0.15 earnings per share. The company’s quarterly revenue was down 31.4% on a year-over-year basis. equities research analysts predict that Applied Genetic Technologies will post -1.14 EPS for the current year.
COPYRIGHT VIOLATION WARNING: This story was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another domain, it was stolen and republished in violation of US and international trademark and copyright law. The original version of this story can be accessed at https://www.dispatchtribunal.com/2017/12/05/applied-genetic-technologies-agtc-receives-media-sentiment-rating-of-0-15.html.
Applied Genetic Technologies Company Profile
Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company develops gene therapy products designed to manage the lives of patients with severe diseases in ophthalmology. As of March 31, 2016, its product candidates included treatments for X-linked retinoschisis (XLRS), over two forms of achromatopsia (ACHM) and X-linked retinitis pigmentosa (XLRP).
Receive News & Ratings for Applied Genetic Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Genetic Technologies Corporation and related companies with MarketBeat.com's FREE daily email newsletter.